Several members of Congress are asking about conflicts of interest at the U.S. Food and Drug Administration after an FDA spokesman, who previously worked as a public relations representative for pharmaceutical companies, used agency email to attack the research of an independent scientist. Douglas Arbesfeld, a senior communications consultant to the FDA, sent an email to reporters attacking Dr.
In the wake of the latest study showing heart attack risk in an FDA-approved drug, there have been increased calls for greater transparency of clinical trial results. What does the U.S. Food and Drug Administration think about requiring companies to publicly release all of their trial results?
The chairperson of the Best Medicines Coalition (BMC), Louise Binder, recently appeared before the Canadian parliament's health committee to argue the case for patients gaining access to newer and more expensive drugs. When asked who funded BMC, Binder told the committee that half its funding came from the government agency, Health Canada, and the remainder was from the drug industry.
"Amid strenuous lobbying across Europe" to end restrictions on direct-to-consumer drug advertising, four pharmaceutical companies are considering launching their own television station.
Thailand's unelected interim government, which was installed after a military coup in September 2006, is "increasingly unpopular at home" and "under attack abroad for overriding drug patents," reports Reuters. So, according to former army chief turned Prime Minister Surayud Chulanont, Thailand will "spend $600,000 on a three-month public relations campaign" to improve the government's poor image. "The money isn't much, but we have to do what we have to do," said Chulanont.